Research Topics
Genomes and Genes | I R ReidSummaryAffiliation: University of Auckland Country: New Zealand Publications
| Collaborators
|
Detail Information
Publications
Role of vitamin D deficiency in cardiovascular diseaseIan R Reid
Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland 1132, New Zealand
Heart 98:609-14. 2012..Trials are underway to assess these possibilities further. At present, there is insufficient evidence to support vitamin D supplementation for improving cardiovascular outcomes...
Pharmacotherapy of Paget's disease of boneIan R Reid
University of Auckland, Faculty of Medical and Health Sciences, Department of Medicine, Private Bag 92019, Auckland, New Zealand
Expert Opin Pharmacother 13:637-46. 2012....
Epidemiology and pathogenesis of osteonecrosis of the jawIan R Reid
Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
Nat Rev Rheumatol 8:90-6. 2012..The management of established ONJ lesions is problematic: the greatest success seems to come from vigorous antimicrobial therapy with judicious use of surgical debridement...
Anti-resorptive therapies for osteoporosisIan R Reid
Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
Semin Cell Dev Biol 19:473-8. 2008..Whether the newer agents can improve on this remains to be seen, though it is possible that anabolic agents which increase bone mass more substantially will be needed to achieve greater reductions in all fracture numbers...
Osteonecrosis of the jaw: who gets it, and why?Ian R Reid
Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
Bone 44:4-10. 2009..This is likely to result in the local release at high concentrations of bisphosphonates. Management focuses on prevention, treatment of infection and cessation of bisphosphonates. The role of surgery is unclear...
Randomized controlled trial of calcium supplementation in healthy, nonosteoporotic, older menIan R Reid
Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand
Arch Intern Med 168:2276-82. 2008..There is no consistent evidence, to our knowledge, that calcium supplementation affects bone mineral density (BMD) in men, despite male osteoporosis being a common clinical problem...
Direct actions of leptin on bone remodelingI R Reid
Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
Calcif Tissue Int 74:313-6. 2004
Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of boneIan R Reid
Department of Medicine, University of Auckland, Private Bag 92019, New Zealand
Bone 35:224-30. 2004..There is no clear evidence from this study that any of these newer markers are superior to total AP in assessing patients with this severity of Paget's disease...
Effects of calcium supplementation on lipids, blood pressure, and body composition in healthy older men: a randomized controlled trialIan R Reid
Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
Am J Clin Nutr 91:131-9. 2010..Calcium supplementation has been suggested to have beneficial effects on serum lipids, blood pressure, and body weight, but these possibilities have not been rigorously assessed in men...
A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal womenIan R Reid
Department of Medicine, University of Auckland, PB 92019, Auckland, New Zealand
Arch Intern Med 164:871-9. 2004..Although many studies have assessed the effects of estrogen and raloxifene hydrochloride on bone mineral density and serum lipid concentrations, there are few direct comparative data...
Effects of calcium supplementation on circulating lipids: potential pharmacoeconomic implicationsIan R Reid
Department of Medicine, University of Auckland, Auckland, New Zealand
Drugs Aging 21:7-17. 2004..Therefore, caution is appropriate in incorporating these findings into clinical practice, but the balance of evidence suggests that calcium is a cost-effective adjunct to the dietary management of hyperlipidaemia...
Pharmacotherapy of osteoporosis in postmenopausal women: focus on safetyIan R Reid
Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
Expert Opin Drug Saf 1:93-107. 2002..While none of these options is suitable for everyone, the range of available therapies does mean that most patients can find an intervention that is effective and acceptable...
Bisphosphonates: new indications and methods of administrationIan R Reid
Department of Medicine, University of Auckland, New Zealand
Curr Opin Rheumatol 15:458-63. 2003..The role of bisphosphonates in osteogenesis imperfecta was further confirmed, and novel roles in ankylosing spondylitis, myelofibrosis, and hypertrophic pulmonary osteoarthropathy were suggested...
Does calcium supplementation increase cardiovascular risk?Ian R Reid
Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
Clin Endocrinol (Oxf) 73:689-95. 2010....
Randomized controlled trial of calcium in healthy older womenIan R Reid
Department of Medicine, University of Auckland, Auckland, New Zealand
Am J Med 119:777-85. 2006..However, these effects are small, it is unknown whether they are sustained with long-term use, they have not been shown with intention-to-treat analyses, and the evidence for fracture prevention with calcium monotherapy is inconsistent...
Osteonecrosis of the jawIan R Reid
Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand
Skeletal Radiol 38:5-9. 2009..Obvious abnormalities are apparent with a variety of radiologic modalities, and it is not clear that radiographs are inferior to other approaches. Most authors favor a conservative approach to surgical debridement of the lesions...
BisphosphonatesIan R Reid
Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand
Skeletal Radiol 36:711-4. 2007
Addition of monofluorophosphate to estrogen therapy in postmenopausal osteoporosis: a randomized controlled trialIan R Reid
Department of Medicine, University of Auckland, Auckland, New Zealand
J Clin Endocrinol Metab 92:2446-52. 2007..EXPERIMENTAL SUBJECTS: Subjects included 80 women with postmenopausal osteoporosis who had been taking estrogen for at least 1 yr...
Obesity and osteoporosisI R Reid
Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand
Ann Endocrinol (Paris) 67:125-9. 2006
Nutrition-related peptides and bone homeostasisIan R Reid
Department of Medicine, University of Auckland, Auckland, New Zealand
J Bone Miner Res 21:495-500. 2006
Comparison of a single infusion of zoledronic acid with risedronate for Paget's diseaseIan R Reid
Department of Medicine, University of Auckland, Auckland, New Zealand
N Engl J Med 353:898-908. 2005..Zoledronic acid, a bisphosphonate administered as a single intravenous infusion, might meet these needs...
Relationships between fat and boneI R Reid
University of Auckland, Auckland, New Zealand
Osteoporos Int 19:595-606. 2008..More immediately, the role of weight maintenance in the prevention of osteoporosis is an important public health message that needs to be more widely appreciated...
Effects of a beta-blocker on bone turnover in normal postmenopausal women: a randomized controlled trialIan R Reid
Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
J Clin Endocrinol Metab 90:5212-6. 2005..beta-blockers increase bone mass in mice, and some observational studies have suggested a beneficial effect of these drugs on bone in humans EXPERIMENTAL SUBJECTS: We studied 41 normal postmenopausal women...
Effect of calcium supplementation on hip fracturesI R Reid
Faculty of Medical and Health Sciences, University of Auckland, Private Bag, 92019 Auckland, New Zealand
Osteoporos Int 19:1119-23. 2008..In addition, those at risk should be looking to other agents with a proven capacity to prevent hip fractures, such as bisphosphonates...
Effects of calcium supplementation on body weight and blood pressure in normal older women: a randomized controlled trialIan R Reid
Department of Medicine, University of Auckland, Private Bag 92019, Auckland 1020, New Zealand
J Clin Endocrinol Metab 90:3824-9. 2005..Epidemiological data suggest that high calcium intakes are associated with decreased body weight and blood pressure. However, there is little evidence from randomized trials that addresses these important issues...
beta-Blocker use, BMD, and fractures in the study of osteoporotic fracturesIan R Reid
Department of Medicine, University of Auckland, Auckland, New Zealand
J Bone Miner Res 20:613-8. 2005..We studied the association of beta-blocker use with BMD and fractures in the Study of Osteoporotic Fractures. beta-blocker use and BMD are unrelated in this cohort, and associations with fracture risk are inconsistent...
Effects of beta-blockers on fracture riskI R Reid
University of Auckland, Auckland, New Zealand
J Musculoskelet Neuronal Interact 8:105-10. 2008..Until there are definitive randomized, controlled trials of beta-blockers, which include fracture as an endpoint, it is unlikely that the current confusing situation will be resolved...
Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studiesIan R Reid
Department of Medicine, University of Auckland, Auckland, New Zealand
J Bone Miner Res 25:2256-65. 2010..Denosumab markedly reduces bone turnover and also reduces fracture numbers. Longer follow-up is necessary to determine how long such low turnover is safe...
Characterization of and risk factors for the acute-phase response after zoledronic acidI R Reid
Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, 1142 Auckland, New Zealand
J Clin Endocrinol Metab 95:4380-7. 2010..Intravenous aminobisphosphonates often cause an acute-phase response (APR), but the precise components of this, its frequency, and the risk factors for its development have not been systematically studied...
Calcium supplementation: balancing the cardiovascular risksIan R Reid
Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
Maturitas 69:289-95. 2011..Patients at high risk of fracture need to take interventions of proven anti-fracture efficacy. Available evidence suggests that this efficacy is not dependent on the co-administration of calcium supplements...
Intravenous zoledronic acid in postmenopausal women with low bone mineral densityIan R Reid
Department of Medicine, University of Auckland, Auckland, New Zealand
N Engl J Med 346:653-61. 2002..Gastrointestinal intolerance limits maximal dosing. Although intermittent intravenous treatments have been used, the optimal doses and dosing interval have not been systematically explored...
Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?Ian R Reid
Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand
Bone 41:318-20. 2007....
A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 yearsIan R Reid
Department of Medicine, University of Auckland, Auckland, New Zealand
J Bone Miner Res 26:2261-70. 2011..01). Bone markers at 6 months were predictive of response duration. These data demonstrate an unprecedented duration of remission of Paget disease following treatment with zoledronic acid, accompanied by an improved quality of life...
Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic DiseaseI R Reid
Department of Medicine, University of Auckland, New Zealand
Lancet 357:509-12. 2001..To assess whether statins have clinically significant effects on bone, we studied the frequency of fractures in a large randomised controlled trial of these agents...
Preventing glucocorticoid-induced osteoporosisI R Reid
Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
Z Rheumatol 59:II/97-102. 2000..It is incumbent on all physicians supervising long-term glucocorticoid therapy to ensure that a skeletal assessment is carried out and that osteoporosis prophylaxis is instituted, where appropriate...
Effects of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism: four-year follow-up and comparison with healthy postmenopausal womenB J Orr-Walker
Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
Arch Intern Med 160:2161-6. 2000..Longer-term data are required to further assess the efficacy of this treatment in chronic stable primary hyperparathyroidism...
Bisphosphonate therapy for secondary osteoporosis: adult perspectiveIan R Reid
Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
Horm Res Paediatr 76:28-32. 2011..Additional effects of aging and menopause can substantially increase an individual's fracture risk. It is important that physicians assess fracture risk in susceptible patients and initiate treatment when indicated...
Pharmacological management of osteoporosis in postmenopausal women: a comparative reviewI R Reid
Department of Medicine, University of Auckland, New Zealand
Drugs Aging 15:349-63. 1999..There is a need for an effective bone anabolic factor but those which have been trialled to date have not proceeded because of significant adverse effects...
Bisphosphonates in the treatment of osteoporosis: a review of their contribution and controversiesIan R Reid
Faculty of Medical and Health Sciences, University of Auckland Auckland, New Zealand
Skeletal Radiol 40:1191-6. 2011....
Cardiovascular effects of calcium supplementationI R Reid
Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
Osteoporos Int 22:1649-58. 2011..Since food sources have not been associated with adverse cardiovascular effects, they may be preferable. Available evidence suggests that other osteoporosis treatments are still effective without calcium co-administration...
A new receptor to turn on bone growthIan R Reid
Department of Medicine, University of Auckland
N Z Med J 115:169-70. 2002
Fat and boneIan R Reid
Department of Medicine, University of Auckland, Auckland, New Zealand
Arch Biochem Biophys 503:20-7. 2010..In the clinic, the key issues are that obesity is protective against osteoporosis, but underweight is a major preventable risk factor for fractures...
Bisphosphonates in Paget's diseaseIan R Reid
Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, New Zealand
Bone 49:89-94. 2011....
Evidence-based policy on dietary calcium and vitamin DIan R Reid
Department of Medicine, University of Auckland, Auckland, New Zealand
J Bone Miner Res 26:452-4. 2011..However, we believe that the central role of sunlight exposure in determining vitamin D status needs to be explicitly reflected in public policy in this area...
Relationships among body mass, its components, and boneI R Reid
Department of Medicine, University of Auckland, New Zealand
Bone 31:547-55. 2002..More immediately, the role of weight maintenance in the prevention of osteoporosis is an important public health message that needs to be more widely appreciated...
Preptin, another peptide product of the pancreatic beta-cell, is osteogenic in vitro and in vivoJ Cornish
Dept of Medicine, Univ of Auckland, Private Bag 92019, Auckland, NZ, USA
Am J Physiol Endocrinol Metab 292:E117-22. 2007..These data demonstrate that preptin, which is cosecreted from the pancreatic beta-cell with amylin and insulin, is anabolic to bone and may contribute to the preservation of bone mass observed in hyperinsulinemic states such as obesity...
Trifluoroacetate, a contaminant in purified proteins, inhibits proliferation of osteoblasts and chondrocytesJ Cornish
Department of Medicine, University of Auckland, Auckland 1001, New Zealand
Am J Physiol 277:E779-83. 1999..Such peptides should be converted to a hydrochloride or biologically equivalent salt before assessment of their biological effects is undertaken...
Systemic administration of a novel octapeptide, amylin-(1---8), increases bone volume in male miceJ Cornish
Department of Medicine, University of Auckland, Auckland 1001, New Zealand
Am J Physiol Endocrinol Metab 279:E730-5. 2000..Amylin-(1---8) thus has significant anabolic effects in vivo, suggesting that this peptide or analogs of it should be further evaluated as potential therapies for osteoporosis...
Hormone replacement therapy causes a respiratory alkalosis in normal postmenopausal womenB J Orr Walker
Department of Medicine, University of Auckland, New Zealand
J Clin Endocrinol Metab 84:1997-2001. 1999..These may contribute to the effects of HRT and menopause on many tissues and disease processes, including the development of osteoporosis...
Determinants of vitamin D status in older women living in a subtropical climateJenny A Lucas
Department of Medicine, University of Auckland, Private Bag 92 019, Auckland, New Zealand
Osteoporos Int 16:1641-8. 2005..Our findings support the suggestion that vitamin D supplementation should become standard practice in this population of women, particularly during winter...
The effect of treatment with a thiazide diuretic for 4 years on bone density in normal postmenopausal womenM J Bolland
Department of Medicine, University of Auckland, Auckland, New Zealand
Osteoporos Int 18:479-86. 2007..The improvements in bone density seen in the first 2 years were sustained throughout the extension study. Thiazides provide a further option in the prevention of postmenopausal bone loss...
Effects of vitamin D supplementation on strength, physical performance, and falls in older persons: a systematic reviewNancy K Latham
Clinical Trials Research Unit, University of Auckland, Auckland, New Zealand
J Am Geriatr Soc 51:1219-26. 2003..identify, appraise, and synthesize data from randomized, controlled trials of vitamin D supplementation in older people...
Prospective 10-year study of the determinants of bone density and bone loss in normal postmenopausal women, including the effect of hormone replacement therapyFiona Wu
Department of Medicine, University of Auckland, New Zealand
Clin Endocrinol (Oxf) 56:703-11. 2002..Good compliance with HRT long-term is achievable. These findings are relevant to deciding the frequency of bone density measurement, and in advising women regarding prevention and treatment of postmenopausal bone loss...
High-dose oral vitamin D3 supplementation in the elderlyC J Bacon
Department of Medicine, University of Auckland, Auckland, New Zealand
Osteoporos Int 20:1407-15. 2009..With baseline 25OHD > 50 nmol/L, vitamin D supplementation does not reduce PTH levels...
Determinants of vitamin D status in older men living in a subtropical climateM J Bolland
Osteoporosis Research Group, Department of Medicine, University of Auckland, Private Bag 92 019, Auckland, New Zealand
Osteoporos Int 17:1742-8. 2006....
Lactoferrin and bone; structure-activity relationshipsJ Cornish
Department of Medicine, University of Auckland, Private Bag 92019 Auckland, New Zealand
Biochem Cell Biol 84:297-302. 2006..We conclude that lactoferrin might have a physiological role in bone growth and healing and a potential therapeutic role as an anabolic factor in osteoporosis...
Systemic administration of adrenomedullin(27-52) increases bone volume and strength in male miceJ Cornish
Department of Medicine, University of Auckland, Auckland, New Zealand
J Endocrinol 170:251-7. 2001..It is concluded that adrenomedullin(27-52) acts as an anabolic agent on bone. These findings may be relevant to the normal regulation of bone mass and to the design of agents for the treatment of osteoporosis...
Leukemia inhibitory factor is mitogenic to osteoblastsJ Cornish
Department of Medicine, University of Auckland, New Zealand
Bone 21:243-7. 1997..They were not found in the acid phosphatase-positive staining osteoclasts. These results indicate that cells which have a mitogenic response to LIF are bone-forming rather than bone-resorbing cells...
Alteration of bone cell function by RANKL and OPG in different in vitro modelsJ M Lin
University of Auckland, Auckland, New Zealand
Eur J Clin Invest 37:407-15. 2007..However, their effects in mature bone cells and in organ cultures have not been well studied. It is uncertain whether their activities in different experimental models are comparable...
Skeletal effects of interventions in mild primary hyperparathyroidism: a meta-analysisShyam Sankaran
Department of Medicine, University of Auckland, Private Bag 92 019, Auckland, New Zealand
J Clin Endocrinol Metab 95:1653-62. 2010..Uncertainty exists as to the optimal management and monitoring of the skeletal consequences of mild primary hyperparathyroidism (PHPT)...
A potential role for adrenomedullin as a local regulator of bone growthD Naot
Department of Medicine, University of Auckland, Auckland 1001, New Zealand
Endocrinology 142:1849-57. 2001....
Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivoJ Cornish
Department of Medicine, University of Auckland, New Zealand
J Endocrinol 175:405-15. 2002..When administered systemically, the direct actions of leptin outweigh its centrally mediated effects on bone, the latter possibly being mediated by leptin's regulation of insulin sensitivity...
Calcium supplementation does not affect CRP levels in postmenopausal women--a randomized controlled trialA Grey
Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
Osteoporos Int 17:1141-5. 2006..Epidemiological studies suggest that calcium supplementation may decrease the risk of cardiovascular disease...
Effects of 25-hydroxyvitamin D level and its change on parathyroid hormone in premenopausal Chinese womenC J Bacon
Department of Medicine, University of Auckland, Auckland, New Zealand
Osteoporos Int 21:1935-41. 2010..Parathyroid hormone (PTH) change at 3 months was associated with change in 25(OH)D but not with baseline levels, and PTH fell even when starting levels of 25(OH)D were >40 nmol/L, consistent with optimal values for 25(OH)D of ?40 nmol/l...
Adrenomedullin--a regulator of bone formationJ Cornish
Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
Regul Pept 112:79-86. 2003..Thus, these small peptides, or their analogues, are attractive candidates as anabolic therapies for osteoporosis...
Effects of calcitonin, amylin, and calcitonin gene-related peptide on osteoclast developmentJ Cornish
Department of Medicine and School of Biological Sciences, University of Auckland, Auckland, New Zealand
Bone 29:162-8. 2001..This activity is shared by amylin and CGRP. The much greater potency of calcitonin than amylin and CGRP is consistent with the action of these peptides being mediated by calcitonin receptors...
Interleukin-18 is a novel mitogen of osteogenic and chondrogenic cellsJ Cornish
Department of Medicine, University of Auckland, Auckland 1001, New Zealand
Endocrinology 144:1194-201. 2003..Combined, these studies indicate that IL-18 may have an autocrine/paracrine mitogen role for both osteogenic and chondrogenic cells, independent of the production of IFNgamma or GM-CSF...
Increased abdominal fat in young women of Indian originBrandon Orr-Walker
Department of Medicine, Faculty of Medicine and Health Sciences, University of Auckland, Auckland, New Zealand
Asia Pac J Clin Nutr 14:69-73. 2005..001), with marked differences evident even in the youngest group (mean age 23 years). Compared to other racial groups, women of Indian origin preferentially accumulate abdominal fat--a trait that is well established in young adulthood...
Actions of fibroblast growth factor-8 in bone cells in vitroJian Ming Lin
Department of Medicine, University of Auckland, Auckland, New Zealand
Am J Physiol Endocrinol Metab 297:E142-50. 2009..These data suggest that FGF-8 may have a physiological role in bone acting in an autocrine/paracrine manner...
Fractures between the ages of 20 and 50 years increase women's risk of subsequent fracturesFiona Wu
Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
Arch Intern Med 162:33-6. 2002..Therefore, this is an important clinical risk factor that points to the need for bone density measurement, consideration of lifestyle modification, and antiosteoporosis therapies in these women...
Spinal bone density in women using depot medroxyprogesterone contraceptionT Cundy
Department of Medicine, The Faculty of Medicine and Health Sciences, University of Auckland, New Zealand
Obstet Gynecol 92:569-73. 1998..To determine factors possibly associated with reduced bone density in women using the injectable contraceptive depot medroxyprogesterone acetate...
Osteoblastic cells express phospholipid receptors and phosphatases and proliferate in response to sphingosine-1-phosphateA Grey
Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
Calcif Tissue Int 74:542-50. 2004....
Parathyroid hormone-related protein-(107-139) inhibits bone resorption in vivoJ Cornish
Department of Medicine, University of Auckland, New Zealand
Endocrinology 138:1299-304. 1997....
In vitro and in vivo effects of adiponectin on boneGarry A Williams
Department of Medicine, University of Auckland, Auckland 1142, New Zealand
Endocrinology 150:3603-10. 2009..Because adiponectin does influence bone mass in vivo, it is likely to be a contributor to the fat-bone relationship...
Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysisMark J Bolland
Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92 019, Auckland 1142, New Zealand
BMJ 341:c3691. 2010..To investigate whether calcium supplements increase the risk of cardiovascular events...
The effect of atorvastatin on markers of bone turnover in patients with type 2 diabetesG D Braatvedt
University Department of Medicine, Auckland Hospital, University of Auckland, Auckland, New Zealand
Bone 35:766-70. 2004..We conclude that atorvastatin (40 mg/day) has no significant effect on bone turnover in man...
Bone mineral density in patients with treated Addison's diseaseG D Braatvedt
Department of Medicine, University of Auckland, Private Bag, Auckland, New Zealand
Osteoporos Int 10:435-40. 1999..Unexpected hypogonadism in men with Addison's disease is common...
Bisphosphonates in pregnancy and lactation-associated osteoporosisS M O'Sullivan
Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
Osteoporos Int 17:1008-12. 2006..The aetiology is uncertain, and its management and natural history poorly defined...
Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiencyAndrew Grey
Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
J Clin Endocrinol Metab 90:2122-6. 2005..Some patients with PHPT may experience an increase in urinary calcium excretion after vitamin D repletion...
Evaluation of the FRAX and Garvan fracture risk calculators in older womenMark J Bolland
Department of Medicine, University of Auckland, Auckland 1142, New Zealand
J Bone Miner Res 26:420-7. 2011..The calibration varied, suggesting that the calculators should be validated in local cohorts before clinical use...
Association of fat-free mass and training status with left ventricular size and mass in endurance-trained athletesGillian A Whalley
Department of Medicine, University of Auckland, Auckland, New Zealand
J Am Coll Cardiol 44:892-6. 2004..We sought to study the relationship between left ventricular (LV) size and body composition in male endurance athletes and age-matched control subjects...
The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal womenAndrew Grey
Department of Medicine, University of Auckland, Private Bag 92 019, Auckland, New Zealand
J Clin Endocrinol Metab 94:538-44. 2009..Annual iv administration of 5 mg zoledronate decreases fracture risk. The optimal dosing interval of 5 mg zoledronate is not known...
Does degree of baldness influence vitamin D status?Mark J Bolland
Department of Medicine, University of Auckland, Auckland, New Zealand
Med J Aust 189:674-5. 2008..To determine the association, if any, between male-pattern hair loss (baldness) and serum 25-hydroxyvitamin D (25-OHD) levels...
The effects of seasonal variation of 25-hydroxyvitamin D on diagnosis of vitamin D insufficiencyMark J Bolland
Osteoporosis Research Group, Department of Medicine, University of Auckland, Private Bag 92 019, Auckland, New Zealand
N Z Med J 121:63-74. 2008..To explore the effects of seasonal variation on the diagnosis of vitamin D sufficiency and to determine whether age, gender, and ethnicity modify these effects...
A randomized controlled trial of estrogen replacement therapy in long-term users of depot medroxyprogesterone acetateTim Cundy
Department of Medicine, Faculty of Medicine and Health Science, University of Auckland, 1001 Auckland, New Zealand
J Clin Endocrinol Metab 88:78-81. 2003..0%, P = 0.029). There were no major adverse events. These data support the view that the likely cause of DMPA-associated bone loss is estrogen deficiency and demonstrate that it can be arrested by estrogen replacement therapy...
Calcium sensing receptor gene A986S polymorphism and responsiveness to calcium supplementation in postmenopausal womenRobert Young
Department of Medicine, University of Auckland, Auckland, New Zealand
J Clin Endocrinol Metab 88:697-700. 2003..These results are in contrast to those in young or premenopausal women, and they provide no support for an important role for the CASR A986S polymorphism in osteoporosis...
Shared pathways of osteoblast mitogenesis induced by amylin, adrenomedullin, and IGF-1Jillian Cornish
Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
Biochem Biophys Res Commun 318:240-6. 2004..Our findings are potentially important in refining these peptides for the therapy of osteoporosis...
Prolonged antiresorptive activity of zoledronate: a randomized, controlled trialAndrew Grey
Department of Medicine, University of Auckland, Auckland, New Zealand
J Bone Miner Res 25:2251-5. 2010..These data demonstrate that the antiresorptive effects of a single 5-mg dose of zoledronate are sustained for 3 years; clinical trials to investigate the antifracture efficacy of dosing intervals longer than 1 year are justified...
alpha -melanocyte-stimulating hormone is a novel regulator of boneJillian Cornish
Department of Medicine, University of Auckland, Auckland 1001, New Zealand
Am J Physiol Endocrinol Metab 284:E1181-90. 2003..The latter result may also be contributed to by alpha-MSH effects elsewhere, such as the adipocyte, pancreatic beta-cell, or central nervous system...
Modulation of osteoclastogenesis by fatty acidsJillian Cornish
Department of Medicine, University of Auckland, Auckland, New Zealand
Endocrinology 149:5688-95. 2008....
Enhanced osteoclastogenesis in patients with tophaceous gout: urate crystals promote osteoclast development through interactions with stromal cellsNicola Dalbeth
University of Auckland, Grafton, Auckland, New Zealand
Arthritis Rheum 58:1854-65. 2008..To analyze cellular mechanisms of bone erosion in gout...
Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trialMark J Bolland
Department of Medicine, University of Auckland, and Department of Infectious Diseases, Auckland Hospital, New Zealand
J Clin Endocrinol Metab 92:1283-8. 2007..Recent studies have reported low bone mineral density (BMD) in HIV-infected patients. Annual iv administration of 4 mg zoledronate has been shown to increase BMD and suppress bone turnover in postmenopausal women...
The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trialAndrew Grey
Department of Medicine, University of Auckland, and LabPlus, Auckland City Hospital, New Zealand
J Clin Endocrinol Metab 92:1305-10. 2007..Human data on the skeletal effects of thiazolidinediones are currently available only from observational studies...
Emerging issues with bisphosphonatesIan R Reid
Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand
Rheum Dis Clin North Am 32:691-702, vi. 2006..It is likely that definitive clinical trial data will not become available to resolve these questions, so careful clinical observation and caution are needed in patients who require treatment over periods of more than 10 years...
Menopausal bone loss in long-term users of depot medroxyprogesterone acetate contraceptionTim Cundy
Department of Medicine, Faculty of Medicine and Health Science, The University of Auckland, and the Family Planning Association of New Zealand
Am J Obstet Gynecol 186:978-83. 2002..The purpose of this study was to determine the rate of early postmenopausal bone loss in women who had used depot medroxyprogesterone acetate contraception through to menopause...
Bone mineral density is not reduced in HIV-infected Caucasian men treated with highly active antiretroviral therapyMark J Bolland
Department of Medicine, University of Auckland, Auckland, New Zealand
Clin Endocrinol (Oxf) 65:191-7. 2006..We sought to determine whether BMD in HIV-infected men treated with HAART for at least 3 months is different from that in healthy controls, and, if so, what HIV-related factors might explain this finding...
Age-, gender-, and weight-related effects on levels of 25-hydroxyvitamin D are not mediated by vitamin D binding proteinMark J Bolland
Department of Medicine, University of Auckland, Auckland, New Zealand
Clin Endocrinol (Oxf) 67:259-64. 2007..We hypothesized that these findings might be explained by effects of these variables on vitamin D binding protein (DBP) levels. We set out to determine the relationships between DBP and gender, 25OHD, body weight and body composition...
Fat mass is an important predictor of parathyroid hormone levels in postmenopausal womenMark J Bolland
Osteoporosis Research Group, Department of Medicine, University of Auckland Private Bag 92 019, Auckland 1020, New Zealand
Bone 38:317-21. 2006..This association between fat mass and PTH might contribute to the association between primary hyperparathyroidism and increased body weight...
The effects of seasonal variation of 25-hydroxyvitamin D and fat mass on a diagnosis of vitamin D sufficiencyMark J Bolland
Department of Medicine, University of Auckland, Auckland, New Zealand
Am J Clin Nutr 86:959-64. 2007..The effect of season on vitamin D status is often overlooked in studies of optimal vitamin D concentrations and in clinical practice...
CLINICAL Review # : low body weight mediates the relationship between HIV infection and low bone mineral density: a meta-analysisMark J Bolland
Osteoporosis Research Group, Department of Medicine, University of Auckland, Private Bag 92 019, Auckland, New Zealand
J Clin Endocrinol Metab 92:4522-8. 2007..The cross-sectional studies may have been confounded by the failure to control for low body weight in HIV-infected patients...
Effect of osteoporosis treatment on mortality: a meta-analysisMark J Bolland
Osteoporosis Research Group, Department of Medicine, University of Auckland, Private Bag 92 019, Auckland, New Zealand
J Clin Endocrinol Metab 95:1174-81. 2010..Conclusions: Treatments for osteoporosis with established vertebral and nonvertebral fracture efficacy reduce mortality in older, frailer individuals with osteoporosis who are at high risk of fracture...
